{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:32:40Z","timestamp":1792481560460,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,24]]},"DOI":"10.7759\/cureus.63047","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T16:05:36Z","timestamp":1719245136000},"source":"Crossref","is-referenced-by-count":1,"title":["A Rare Case of Paraganglioma Syndrome Associated With Polycythemia and Blindness"],"prefix":"10.7759","author":[{"given":"Yumiko","family":"Esaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Harbuz-Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181ebb4f0","article-title":"The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors. Pheochromocytoma, paraganglioma, and medullary thyroid cancer","volume":"39","author":"Chen H","year":"2010","unstructured":"Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors. Pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010, 39:775-83. 10.1097\/MPA.0b013e3181ebb4f0","journal-title":"Pancreas"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"N\u00f6lting S","year":"2022","unstructured":"N\u00f6lting S, Bechmann N, Taieb D, et al.. Personalized management of pheochromocytoma and paraganglioma. Endocr Rev. 2022, 43:199-239. 10.1210\/endrev\/bnab019","journal-title":"Endocr Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205119","article-title":"Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia","volume":"367","author":"Zhuang Z","year":"2012","unstructured":"Zhuang Z, Yang C, Lorenzo F, et al.. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med. 2012, 367:922-30. 10.1056\/NEJMoa1205119","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.1912","article-title":"New syndrome of paraganglioma and somatostatinoma associated with polycythemia","volume":"31","author":"Pacak K","year":"2013","unstructured":"Pacak K, Jochmanova I, Prodanov T, et al.. New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol. 2013, 31:1690-8. 10.1200\/JCO.2012.47.1912","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2600","article-title":"Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome","volume":"99","author":"Buffet A","year":"2014","unstructured":"Buffet A, Smati S, Mansuy L, et al.. Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome. J Clin Endocrinol Metab. 2014, 99:E369-73. 10.1210\/jc.2013-2600","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31839","article-title":"Nonmosaic somatic HIF2A mutations associated with late onset polycythemia-paraganglioma syndrome: newly recognized subclass of polycythemia-paraganglioma syndrome","volume":"125","author":"Pang Y","year":"2019","unstructured":"Pang Y, Gupta G, Jha A, et al.. Nonmosaic somatic HIF2A mutations associated with late onset polycythemia-paraganglioma syndrome: newly recognized subclass of polycythemia-paraganglioma syndrome. Cancer. 2019, 125:1258-66. 10.1002\/cncr.31839","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.144368","article-title":"Developmental vascular malformations in EPAS1 gain-of-function syndrome","volume":"6","author":"Rosenblum JS","year":"2021","unstructured":"Rosenblum JS, Wang H, Dmitriev PM, et al.. Developmental vascular malformations in EPAS1 gain-of-function syndrome. JCI Insight. 2021, 6:144368. 10.1172\/jci.insight.144368","journal-title":"JCI Insight"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2019.5244","article-title":"Vascular changes in the retina and choroid of patients with EPAS1 gain-of-function mutation syndrome","volume":"138","author":"Dmitriev PM","year":"2020","unstructured":"Dmitriev PM, Wang H, Rosenblum JS, et al.. Vascular changes in the retina and choroid of patients with EPAS1 gain-of-function mutation syndrome. JAMA Ophthalmol. 2020, 138:148-55. 10.1001\/jamaophthalmol.2019.5244","journal-title":"JAMA Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvad066","article-title":"European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"189","author":"Fassnacht M","year":"2023","unstructured":"Fassnacht M, Tsagarakis S, Terzolo M, et al.. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023, 189:G1-G42. 10.1093\/ejendo\/lvad066","journal-title":"Eur J Endocrinol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders JW","year":"2014","unstructured":"Lenders JW, Duh QY, Eisenhofer G, et al.. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014, 99:1915-42. 10.1210\/jc.2014-1498","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-012-0967-z","article-title":"A novel EPAS1\/HIF2A germline mutation in a congenital polycythemia with paraganglioma","volume":"91","author":"Lorenzo FR","year":"2013","unstructured":"Lorenzo FR, Yang C, Ng Tang Fui M, et al.. A novel EPAS1\/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl). 2013, 91:507-12. 10.1007\/s00109-012-0967-z","journal-title":"J Mol Med (Berl)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-20-0280","article-title":"Functional significance of germline EPAS1 variants","volume":"28","author":"Dwight T","year":"2021","unstructured":"Dwight T, Kim E, Bastard K, et al.. Functional significance of germline EPAS1 variants. Endocr Relat Cancer. 2021, 28:97-109. 10.1530\/ERC-20-0280","journal-title":"Endocr Relat Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.04.012","article-title":"Somatic mosaicism of EPAS1 mutations in Pacak-Zhuang syndrome","volume":"28","author":"Wang H","year":"2022","unstructured":"Wang H, Zhuang Z, Rosenblum JS, Pacak K. Somatic mosaicism of EPAS1 mutations in Pacak-Zhuang syndrome. Endocr Pract. 2022, 28:734-5. 10.1016\/j.eprac.2022.04.012","journal-title":"Endocr Pract"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-23-0050","article-title":"Pacak-Zhuang syndrome: a model providing new insights into tumor syndromes","volume":"30","author":"Rosenblum JS","year":"2023","unstructured":"Rosenblum JS, Wang H, Nazari MA, Zhuang Z, Pacak K. Pacak-Zhuang syndrome: a model providing new insights into tumor syndromes. Endocr Relat Cancer. 2023, 30:e230050. 10.1530\/ERC-23-0050","journal-title":"Endocr Relat Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110051","article-title":"Belzutifan, a potent HIF2\u03b1 inhibitor, in the Pacak-Zhuang syndrome","volume":"385","author":"Kamihara J","year":"2021","unstructured":"Kamihara J, Hamilton KV, Pollard JA, et al.. Belzutifan, a potent HIF2\u03b1 inhibitor, in the Pacak-Zhuang syndrome. N Engl J Med. 2021, 385:2059-65. 10.1056\/NEJMoa2110051","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/206985-a-rare-case-of-paraganglioma-syndrome-associated-with-polycythemia-and-blindness","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T16:05:40Z","timestamp":1719245140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/206985-a-rare-case-of-paraganglioma-syndrome-associated-with-polycythemia-and-blindness"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.63047","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,24]]}}}